APA (7th ed.) Citation

L, Y., R, T., Y, S., Y, L., & Y, M. (2026). MRPL3 is identified as a prognostic biomarker and therapeutic target in lung adenocarcinoma via a lactylation-disulfidptosis gene signature model and experimental validation. Frontiers in immunology, 17, 1772955. https://doi.org/10.3389/fimmu.2026.1772955

Chicago Style (17th ed.) Citation

L, Yin, Tang R, Song Y, Liu Y, and Ma Y. "MRPL3 Is Identified as a Prognostic Biomarker and Therapeutic Target in Lung Adenocarcinoma via a Lactylation-disulfidptosis Gene Signature Model and Experimental Validation." Frontiers in Immunology 17 (2026): 1772955. https://doi.org/10.3389/fimmu.2026.1772955.

MLA (9th ed.) Citation

L, Yin, et al. "MRPL3 Is Identified as a Prognostic Biomarker and Therapeutic Target in Lung Adenocarcinoma via a Lactylation-disulfidptosis Gene Signature Model and Experimental Validation." Frontiers in Immunology, vol. 17, 2026, p. 1772955, https://doi.org/10.3389/fimmu.2026.1772955.